Malignant ovarian germ cell tumors: the KK Hospital Experience

Ovarian germ cell malignancies pose a therapeutic challenge especially amongst young patients. This is a retrospective review of 49 patients treated for such malignancies at KK Women's and Children's Hospital over a 13-year period. The relative proportion of such tumors was 6.2%. Age at presentation ranged from 14 to 51 years (mean 25.4 years). Forty-nine percent of tumors were immature teratomas and 81.6% had stage I disease. All patients had surgery initially and 67.3% required postoperative adjuvant chemotherapy. The patients were followed-up for one to 145 months (mean 51.6 months). All the 87.8% of patients on follow-up are alive and disease-free. There was one recurrence. Five patients had eight successful pregnancies, with no congenital anomalies. Mean duration when menstruation was resumed and regular was 2.5 and 3.5 months, respectively. With combination chemotherapy and conservative surgery, the outlook for patients is excellent, with emphasis on preservation of ovarian function and fertility.

Germ cell tumor; Germ cell malignancy; Ovarian germ cell; Malignant ovarian germ cell tumor; Fertility sparing surgery; Menstrual function

[1] Serov S. F., Scully R. E., Sobin L. J.: "Histological typing of ovarian tumors". In: World Health Organization. International histological classification of tumors. Geneva: The World Health Organization. 1973, no. 9.

[2] Wu P. C.,H uang R.L .,L ang J. H. et al.: "Treatment of malignant ovarian germ cell tumours with preservation of fertility: A report of 28 cases". Gynecol. Oneal., 1991; 40, 2.

[3] National Institutes of Health Consensus Development Panel on Ovarian Cancer. NIH consensus conference. Ovarian cancer. Screening, treatment and follow-up. JAMA, 1995; 8, 491.

[4] Gershenson D. M.: "Management of early ovarian cancer: germ cell and sex cord-stromal tumors". Gynecol. Oneal., 1994, 55,S 62-72.

[5] Gershenson D. M.: "Update on malignant ovarian germ cell tumors". Cancer, 1993, 71, 1581.

[6] Schwartz P. E.,C hambers S. K.,C hamber J.T .,K ohom E.,M cintosh S.: "Ovarian germ cell malignancies: the Yale University experience". Gynecol. Onco/., 1992, 45, 26.

[7] Asadourian L.A.,T aylor H.B.: "Dysgerrninoma: an analysis of 105 cases". Obstet. Gynecol., 1969, 33, 370.

[8] De Palo G., Pilotti S., Kenda R.: "Natural history of dysgerminoma". Am. J. Obstet. Gynecol., 1982, 143, 799.

[9] Weinstein D., Polishuk W. Z.: "The role of wedge resection of the ovary as a cause for mechanical sterilty". Surg. Obstet. Gynecol., 1975, 141, 417.

[10] Maiman M., Seltzer V., Boyce J.: "Laparoscopic excision of ovarian neoplasms subsequently found to be malignant". Obstet. Gynecol., 1991, 77, 563-565.

[11] Bjorkholm E., Lundell M., Gyftodimos A., Silfversward C. : "Dysgerminoma. The Radiumhemmet series 1927-1984", Cancer, 1990, 65, 38.

[12] Segelov E.,C ampbell J.,N g M.,T attersall M., Rome R.,F ree K. et al.: "Cisplatin-based chemotherapy for ovarian germ cell malilgnancies: the Australian experience". J. Clin. Oneal., 1994, 12, 378.

[13] Dimopoulos M.A., Papdopoulou M.,A ndreopoulou E., Papadimitriou C., Pavlidid N., Aravantinos G. et al.: "Favourable outcome of germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group Study". Gynecol. Oneal., 1998, 70, 70.

[14] Williams S. D.,B irch R., Einhorn L.H ., Irwin L., Greco F. A., Loehrer P. J:. "Treatment of disseminated germ-cell tumours with cisplatin, bleomycin, and either vinblastine or etoposide". N. En gl. J. Med., 1987, 316, 1435.

[15] Gershenson D. M.,M orris M.,C angirA ., Kavanagh J. J.,S tringer C. A., Edwards C. L.: "Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin". J. Clin. Oncol., 1990, 8, 715.

[16] Kawai M., Kano T., Kikkawa F. et al.: "Seven tumor markers in benign and malignant germ cell tumors of the ovary". Gynecol. Oncol., 1992, 45, 248.

[17] Pressley R.H.,M untz H. G.,F alkenberry S., Rice L. W.: "Serum lactic dehydrogenase as a tumor marker in dysgerminoma". Gynecol. Oncol., 1992, 44, 281.

[18] Kawai M., Furuhashi Y., Kano T. et al.: "Alpha-fetoprotein in malignant germ cell tumors of the ovary". Gynecol. Oncol., 1990, 39,160.

[19] Bonazzi C.,C olombo N.,L issoni A. et al.: "Alpha-fetoprotein in the management of germ cell tumors of the ovary". J. Nucl. Med. Allied. Sci., 1989, 33 (3 suppl), 53.

[20] Dgani R., Shoham Z., Czernobilsky B. et al.: "The content of lactic dehydrogenase, alkaline phosphatase and human chorionic gonadotropin in a pure ovarian dysgerminoma". Gvnecol. Oneal., 1988, 30, 44.

[21] Williams S. D., Blessing J. A., Di Saia P. J., Major F. J., Ba11 H. G 3rd, Liao S. Y.: "Second-look laparotomy in ovarian germ celltumors: the Gynecologic Oncology Group experience". Gynecol Oncnl., 1994, 52:3, 287.

[22] Berek J. S, Hacker N. F.:''Non-epithelial ovarian and fallopian tube cancers. In: Berek S, Hacker NF, eds." Practical gynecologic oncology., 3rd ed., Philadelphia，Lippincott Williams and Wilkins, 2000, 523

[23] Low J. J. H., Perrin L. C., Crandon A. J., Hacker N. F.: "Conservative surgery to preserve ovarian function in patients with malil gnant ovarian germ ce11 tumors“ Cancer,2000, 89, 391.

[24] Gershenson D. M.: "Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumours". J. Clin. Oneal.. 1988, 6, 270.

[25] Schartz P.: "Combination chemotherapy in the management of ovarian germ cell malignancies". Obstet. Gynecol., 1984, 64, 564

[26] F ishman D. A., Schwartz P. E.: "Current approach to diagnosis and treatment of ovarian germ cell malignancies". Cun: Opin Obstet. Gynecol., 1994, 6, 98.

[27] Creasman W. T., Soper J.T.: "Assessment of the contemporary management of germ cell malignancie、of the ovary". Am. J Obstet. Gynecol., 1985, 153, 828.

[28] Sessa C., Bonazzi C., Landoni F., Pecorelli S., Sartori E., Mangioni C.: "Cisplatin, vinblastine and blcomycin combination chemotherapy in endodermal sinus tumor of the ovary". Obstet. Gynecol., 1987, 70, 220.